Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Cancer. 2015 Jun 19;121(19):3455–3464. doi: 10.1002/cncr.29538

Table 3.

Three-year progression-free survival rates among patients with OPC by tumor HPV DNA status or pretreatment serum HPV DNA status and smoking status

3-year progression-free survival,
% (95% CI)
P
All patients
 Tumor HPV DNA status/smoking status
  HPV+/≤10 pack-years 90.5 (78.6–95.9) Reference
  HPV+/>10 pack-years 78.6 (61.6–88.7) 0.887
  HPV− 71.9 (47.7–86.3) 0.146
0.430a
 Serum HPV DNA status/smoking status
  HPV+/≤10 pack-years 86.1 (75.6–92.3) Reference
  HPV+/>10 pack-years 81.3 (66.0–90.2) 0.905
  HPV− 84.9 (75.4–91.0) 0.879
0.977a
Only patients with HPV+ tumors
 Serum HPV DNA status
  HPV− 91.3 (75.4–97.1) Reference
  HPV+ 82.1 (69.2–90.0) 0.800
a

Test for trend.